Genset appoints new leader
French biotechnology company Genset has appointed Denis Ravel to lead the development of Famoxin, Genset's flagship antiobesity drug. The appointment comes after six key workers, including Famoxin discoverer Bernard Bihain, left the company. However, Andre Pernet, ceo of Genset, said the company remained on schedule to begin clinical trials of the drug later this year and added that the company still has more than 250 researchers, 40 of whom are working on Famoxin.